Initial evaluation of the therapeutic efficacy of 177Lu-FAPI in patients with various end-stage metastatic cancers resistant to standard therapies

Iran University of Medical Sciences0 个研究点目标入组 10 人开始时间: 待定最近更新: 2023年8月21日

试验速览

暂无简介。

•the patient should be able to understand and sign off the informed consent.
•The patient should be able to understand and follow the treatment protocol.
•Patients should be older than 18.
•The patients life expectancy should be over 6 months.
•patients should show no response to the standard treatment.
•The 68Ga-FAPI PET scan or 99mTc-FAPI SPECT scan should show 3 times more uptake of radiopharmaceutical in tumor to liver of the patients.
•the patient with progressive disease should be included.

•The patients who have received therapeutic radiopharmaceuticals like, 223Ra, 188Re, 186Re, 153Sm during last 6 months.
•The patients are under systemic therapies like chemotherapy, immunotherapy, or biological treatment for cancer.
•The patients who have been under any research treatment during 28 days before entrance in this study.
•The patients who have shown any known allergy to the therapeutic radiopharmaceuticals.
•The patients who have congestive heart failure.

发起方